Alterations in the RAS/MAP kinases pathway led to the development of specific drugs, targeting EGFR mutations, MET exon14 skipping, ALK/RET/ROS1/NTRKs fusions and recently the KRAS G12C mutation hotspot; therefore, lung adenocarcinoma is the solid tumor with the highest number of validated targeted therapies, and thus it is a genomic model of mutation-driven cancer therapy for metastatic disease [4]. This evidence concerns the gene EGFR and metastatic neoplasm.